Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($2.25), $0.16 worse than the analyst estimate of ($2.09). Revenue for the quarter came in at $108.3 million versus the consensus estimate of $107.1 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.